Get the Stockscreener App
1.91
5.52%
0.10
Biocardia Inc stock is traded at $1.91, with a volume of 65,342.
It is up +5.52% in the last 24 hours and down -16.78% over the past month.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
See More
Previous Close:
$1.81
Open:
$1.84
24h Volume:
65,342
Relative Volume:
0.22
Market Cap:
$11.08M
Revenue:
$468.00K
Net Income/Loss:
$-10.34M
P/E Ratio:
-0.2709
EPS:
-7.05
Net Cash Flow:
$-8.94M
1W Performance:
-0.52%
1M Performance:
-16.78%
6M Performance:
-17.32%
1Y Performance:
-29.26%
1-Day Range:
$1.8001
$1.94
1-Week Range:
$1.79
$1.94
52-Week Range:
$1.625
$4.66
Biocardia Inc Stock (BCDA) Company Profile
Name
Biocardia Inc
Sector
Industry
Phone
650-226-0123
Address
320 SOQUEL WAY, SUNNYVALE, CA
Compare BCDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
0.92 | 1.26B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.58 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.53 | 110.24M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1668 | 351.80M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.24 | 0 | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-21 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Stock (BCDA) Latest News
What makes BioCardia Inc. stock price move sharplyJuly 2025 EndofMonth & Free Safe Capital Growth Stock Tips - beatles.ru
BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results - ADVFN Brasil
Real time breakdown of BioCardia Inc. stock performancePortfolio Risk Report & Intraday High Probability Alerts - Newser
BioCardia Inc.’s volatility index tracking explained2025 Big Picture & Fast Gain Swing Alerts - Newser
What moving averages say about BioCardia Inc.Weekly Risk Summary & Daily Technical Forecast Reports - Newser
Technical signs of recovery in BioCardia Inc.July 2025 Outlook & Growth Focused Entry Reports - Newser
Using data tools to time your BioCardia Inc. exitEarnings Miss & Community Supported Trade Ideas - Newser
BioCardia, CART-Tech Partner to Develop, Commercialize Heart3D Fusion Imaging for Interventional Cardiology - Diagnostic and Interventional Cardiology
Cardiol Therapeutics shares rise 1.49% premarket after BioCardia and CART-Tech announce exclusive development and commercialization agreement for Heart3D Fusion Imaging. - AInvest
Should you wait for a breakout in BioCardia Inc.Inflation Watch & Low Volatility Stock Recommendations - Newser
Is BioCardia Inc. forming a reversal patternMarket Risk Report & Smart Investment Allocation Tips - Newser
BioCardia Partners with CART-Tech for Heart3D™ Imaging - MSN
BioCardia Advances Clinical Trials Amid Financial Challenges - TipRanks
BioCardia, CART-Tech Partner To Develop Heart3D Fusion Imaging For Interventional Cardiology - Nasdaq
BioCardia, CART-Tech Partner on Heart3D Fusion Imaging for Interventional Cardiology - AInvest
Why BioCardia Inc. stock attracts strong analyst attentionCPI Data & Consistent Income Trade Ideas - thegnnews.com
BioCardia, CART-Tech enter exclusive agreement for Heart3D Fusion Imaging - TipRanks
BioCardia, Inc. (NASDAQ:BCDA) Q2 2025 Earnings Call Transcript - Insider Monkey
BioCardia and CART-Tech Announce Exclusive Partnership to Develo - GuruFocus
BioCardia and CART-Tech Partner to Develop and Commercialize Heart3D Fusion Imaging for Interventional Cardiology - AInvest
BioCardia and CART-Tech Announce Exclusive Partnership to - GlobeNewswire
BioCardia and CART-Tech, B.V Announce Exclusive Partnership to Develop and Commercialize Heart3D Fusion Imaging for Interventional Cardiology - MarketScreener
BioCardia Inc. Breaks Below Key Support LevelOversold Recovery Opportunity Stocks Attract Buyers - sundaytimes.kr
Biocardia CEO Peter Altman acquires $1,488 in common stock - MSN
BioCardia (BCDA) Advances with Promising Trial Results and Strat - GuruFocus
BioCardia (BCDA) CEO Altman buys $700 in shares By Investing.com - Investing.com Nigeria
BioCardia (BCDA) CEO Altman buys $700 in shares - Investing.com India
Is BioCardia Inc. still worth holding after the dipValue Holding Return Summary With Outlook - Newser
BioCardia outlines regulatory milestones and targets FDA and PMDA submissions for CardiAMP and Helix in Q4 2025 - MSN
Biocardia 2024 Q2 Earnings Improved Losses Amidst Revenue Decline - AInvest
BioCardia sets Q4 2025 for FDA and PMDA submissions for CardiAMP and Helix trials. - AInvest
How BioCardia Inc. stock performs during market volatility5-Year Price Trend Summary and Analysis - Newser
BioCardia's (BCDA) Q2 2025 Earnings and Strategic Pivots in Cardiac Regeneration: A Deep Dive into Long-Term Investment Potential - AInvest
BioCardia's 2025 Q2 Earnings Call: Navigating Contradictions in CardiAMP's Regulatory Journey - AInvest
Earnings call transcript: BioCardia Q2 2025 reveals increased R&D expenses By Investing.com - Investing.com Canada
Earnings call transcript: BioCardia Q2 2025 reveals increased R&D expenses - Investing.com
BioCardia Reports Q2 GAAP EPS of -$0.40, Net Cash Used in Operations Increases - AInvest
BioCardia Inc reports results for the quarter ended June 30Earnings Summary - TradingView
BioCardia Narrows Loss in Fiscal Q2 - The Globe and Mail
BioCardia, Inc. SEC 10-Q Report - TradingView
BioCardia Reports Q2 2025 Business Highlights, Seeks FDA Approval for CardiAMP System - AInvest
Full technical analysis of BioCardia Inc. stockFree Verified Signal From Chart Patterns - Newser
Is BioCardia Inc. meeting your algorithmic filter criteriaPredictive Screener for Daily Trade Watch - Newser
Can momentum traders help lift BioCardia Inc.Chart Confirmation Setup with ROI Signals - Newser
Real time social sentiment graph for BioCardia Inc.AI Pattern Recognition and Trade Prediction - Newser
What institutional flow reveals about BioCardia Inc.Free Chart Alert System With Entry Targets - Newser
Can BioCardia Inc. recover in the next quarterMarket Sentiment Tracker with Smart Alerts - Newser
BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 - The Globe and Mail
Has BioCardia Inc. formed a bullish divergenceFree News Based Entry Opportunity Alerts - Newser
What candlestick patterns are forming on BioCardia Inc.Day Trading Setup Forecast with Trend Model - Newser
Biocardia Inc Stock (BCDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biocardia Inc Stock (BCDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Altman Peter | President and CEO |
Aug 12 '25 |
Buy |
1.75 |
400 |
700 |
167,962 |
| Altman Peter | President and CEO |
Aug 11 '25 |
Buy |
1.76 |
1,700 |
2,989 |
167,562 |
| McClung David | Chief Financial Officer |
Jun 30 '25 |
Buy |
2.08 |
4,819 |
9,999 |
47,950 |
| Altman Peter | President and CEO |
Jun 30 '25 |
Buy |
2.08 |
24,096 |
49,999 |
165,862 |
| STERTZER SIMON H | Director |
Jun 30 '25 |
Buy |
2.08 |
72,289 |
150,000 |
192,654 |
| Blank Andrew Scott | Director |
Jun 30 '25 |
Buy |
2.08 |
72,289 |
150,000 |
346,023 |
| Altman Peter | President and CEO |
May 30 '25 |
Buy |
2.21 |
100 |
221 |
141,766 |
| Altman Peter | President and CEO |
May 20 '25 |
Buy |
2.08 |
1,600 |
3,328 |
140,966 |
| Altman Peter | President and CEO |
May 22 '25 |
Buy |
1.89 |
700 |
1,323 |
141,666 |
| Altman Peter | President and CEO |
May 16 '25 |
Buy |
2.43 |
300 |
730 |
139,366 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):